The U.S. FDA has lifted the clinical hold on Novavax's combination COVID-19 and flu vaccine, allowing the company to resume trials. This combination shot aims to streamline immunizations by targeting both viruses in a single dose, potentially improving vaccination rates and convenience for patients. Novavax’s research now moves forward with hopes of providing a dual-protection option in the near future.